ASH Clinical News June 2015 | Page 32

When faced with overactive signaling . . .

Indications and Usage
Jakafi is indicated for treatment of patients with
polycythemia vera who have had an inadequate
response to or are intolerant of hydroxyurea.

Important Safety Information
Treatment with Jakafi can cause thrombocytopenia,
anemia and neutropenia, which are each dose-related
effects. Perform a pre-treatment complete blood count
(CBC) and monitor CBCs every 2 to 4 weeks until
doses are stabilized, and then as clinically indicated
Manage thrombocytopenia by reducing the dose or
temporarily interrupting Jakafi. Platelet transfusions
may be necessary
Patients developing anemia may require blood
transfusions and/or dose modifications of Jakafi

Jakafi is a registered trademark of Incyte Corporation.
© 2015, Incyte Corporation. All rights reserved. RUX-1452a 03/15

Severe neutropenia (ANC <0.5 X 109/L) was generally
reversible by withholding Jakafi until recovery
Serious bacterial, mycobacterial, fungal and viral infections
have occurred. Delay starting Jakafi until active serious
infections have resolved. Observe patients receiving Jakafi
for signs and symptoms of infection and manage promptly
Tuberculosis (TB) infection has been reported. Observe
patients taking Jakafi for signs and symptoms of active TB
and manage promptly. Prior to initiating Jakafi, evaluate
patients for TB risk factors and test those at higher risk for
latent infection. Consult a physician with expertise in the
treatment of TB before starting Jakafi in patients with
evidence of active or latent TB. Continuation of Jakafi
during treatment of active TB should be based on the
overall risk-benefit determination
Progressive multifocal leukoencephalopathy (PML) has
occurred with ruxolitinib treatment for myelofibrosis.
If PML is suspected, stop Jakafi and evaluate
Advise patients about early signs and symptoms of
herpes zoster and to seek early treatment